Prevalencia de síndrome Metabólico en pacientes VIH (+) usuarios de terapia antiretroviral
Resumen
Introducción: En pacientes VIH (+) se han observado fenómenos cardio-metabólicos en los que el uso de terapia antirretroviral (TARV) tiene un rol fundamental.
Objetivos: Determinar la prevalencia de síndrome Metabólico (SM) en pacientes VIH (+) usuarios de TARV pertenecientes al servicio de Infectología del Hospital Gustavo Fricke entre los años 2013 y 2016.
Materiales y Métodos: Estudio analítico retrospectivo realizado con 211 pacientes VIH (+) pertenecientes al servicio de Infectología del Hospital Gustavo Fricke entre los años 2013 y 2016. Se analizaron variables clínicas, de laboratorio y relacionadas con la infección por VIH.
Resultados: De 211 pacientes, 86.7% eran usuarios de TARV y su uso se asoció a mayor prevalencia de SM, (19.4% en comparación a 3.7%, p=0.044).
Discusión: La prevalencia global de SM fue menor a lo descrito en relación a la población general del mismo grupo etario. Dentro de los usuarios de TARV, su prevalencia fue significativamente mayor destacando alta tasa de hipertrigliceridemia y HDL disminuido. Considerar esta situación para prevenir fenómenos cardiogénicos podría mejorar la calidad a largo plazo de los pacientes VIH (+).
Palabras clave:
virus de la inmunodeficiencia humana, terapia antiretroviral, síndrome metabólicoReferencias
(1) Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, Dansereau EA, Graetz N, Barber RM, Brown JC, Wang H, Duber HC, Naghavi M, Dicker D, Dandona L, Salomon JA, Heutan KR, Foreman K, Phillips DE, Fleming TD, Flaxman AD, Phillips BK, Johnson EK, Coggeshall MS, Abd-Allaht F, Abera SF, Abraham JP, Abubakart I, Abu-Raddad LJ, Abu-Rmeileht NM et al. Global, regional, and nationalincidence and mortalityfor HIV, tuberculosis, and malaria during 1990– 2013: a systematic analysis for the. Global Burden of Disease Study. 2013. Lancet. 2014; 384: 1005–1070.
(2) Jaggers JR, Prasad VK, Dudgeon WD, Blair SN, Sui X, Burgess S, Hand GA. Associationsbetweenphysicalactivity and sedentary time oncomponents of metabolic síndrome among adults with HIV. AIDS 2014; 1387–1392.
(3) De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte Ad, Fontas E, Law MG, Friis-Møller N, Phillips A. Incidence and riskfactorsfor new-onset diabetes in HIV-infectedpatients: the Data Collectionon Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008; 31: 1224–1229.
(4) Syed FF, Sani MU. Recentadvances in HIVassociated cardiovascular diseases in Africa. Heart. 2013;99: 1146–1153.
(5) Centers for Disease Control and Prevention (CDC). Revised surveillance case definition for HIV infection--United States, 2014. MMWR Recomm Rep. 2014; 63: 1.
(6) World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunologic classification of HIV-related disease in adults and children. Geneva: World Health Organization; 2007. pp. 1-48.
(7) Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012; 308: 387-402.
(8) Ministerio de Salud. Guía MINSAL Enfoque de riesgo para la prevención de enfermedades cardiovaculares. Santiago de Chile: Ministerio de Salud; 2014.
(9) Guevara F, Orlando A, Cañón B, Liévano MC, Lombo B, Rendón I, Blanco F . Prevalencia de síndrome metabólico en pacientes infectados con VIH: Utilizando los criterios del ATP III y de la IDFUsing ATP III and IDF criteria. Acta Med Colomb. 2008; 33(4): 282-288.
(10) Nguyen KA, Peer N, Mills EJ, Kengne AP. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. PLoS ONE. 2016; 11: 211-224.
(11) DHHS Panel en Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. USA: Department of Health and Human Services; 2013.
(12) Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolics yndrome in HIVinfected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations withi nsulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care. 2007; 30: 113-19.
(13) Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS. 2003; 17: 141–148,
(14) Madge S, Kinloch-de-Loes S, Mercey D, Jonson M, Séller I. Lipodystrophy in patients naïve to HIV protease inhibitors. AIDS. 1999; 13: 735-7.
(15) Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect Dis. 2014; 58: e1-e34.
(16) Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: the Swiss HIV cohort study. Circulation. 1999; 100: 700–705.
(17) Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, Paredes R, Bakowska E, Engsig FN, Phillips A. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. INSIGHT SMART, ESPRIT Study Groups. AIDS. 2013 Mar; 27; 27(6): 973-9.
(18) Orkin C, Dejesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatmentnaive patients in the ARTEMIS trial. HIV Med. 2013; 14(1): 49-59.
(19) Lafeuillade A, Jolly P, Chadapaud S, Hittinger G, Lambry V, Philip G. Evolution of lipid abnormalities in patients switched from Stavudine- to tenofovir-containing regimens. J Acquir Immune Defic Syndr. 2003; 33: 544–546.
(20) Wada N, Jacobson LP, Cohen M, French A, Phair J, Muñoz A. Cause-specific mortality among HIVinfected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS. 2014 Ene; 14; 28(2): 257-65.
